- AstraZeneca India reported a net income of 558.3 million rupees for the first quarter of 2025.
- This marks a significant improvement compared to a loss of 117.9 million rupees in the same quarter of the previous year.
- The company’s revenue reached 5.26 billion rupees, showing a 36% increase year-over-year.
- Total costs for the quarter amounted to 4.62 billion rupees, up by 31% compared to the previous year.
- AstraZeneca India’s shares increased by 4.4%, reaching 8,784 rupees with a trading volume of 35,349 shares.
- There were no new buy, hold, or sell recommendations reported for the shares.
A look at Astrazeneca Pharma India Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Astrazeneca Pharma India shows a positive long-term outlook. The company scores well in terms of resilience and dividends, indicating a strong ability to weather challenges and provide returns to shareholders. Additionally, with a decent momentum score, Astrazeneca Pharma India is showing potential for future growth in the market.
Astrazeneca Pharma India Ltd is a manufacturer of basic drugs, pharmaceutical formulations, and chemicals. Some of its popular products include Betaloc Durules, Sensorcaine, and Theobric. With a diverse product portfolio, the company is positioned to capitalize on opportunities in the pharmaceutical industry. Overall, Astrazeneca Pharma India‘s performance across different factors suggests a promising future ahead.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
